Evidence map›Paper›PMID 40856754›Full record

ReviewNanomedicine (London, England)2025

Emerging anti-inflammatory nanosystems targeted to the brain.

Arun Kumar Mahanta, Avinash Gothwal, Bivek Chaulagain, Chinenye Edith Muolokwu, Benjamin Tagoe, Babita Lamsal, Matheus Belin, Jagdish Singh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Arun Kumar MahantaDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.
Avinash GothwalDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.
Bivek ChaulagainDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.
Chinenye Edith MuolokwuDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.
Benjamin TagoeDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.
Babita LamsalDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.
Matheus BelinDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.
Jagdish SinghDepartment of Pharmaceutical Sciences, School of Pharmacy, College of Health and Human Sciences, North Dakota State University, Fargo, ND, USA.

Funding

Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into BrainR01AG083981 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI Takahisa Kanekiyo, Jagdish Singh · 2023 to 2026
$2.4M
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's DiseaseRF1AG068034 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2021 to 2022
$1.6M
Enhanced APOE2 Expression into Brain for Therapeutic Strategy for Alzheimer's DiseaseR01AG068034 · NIA · NORTH DAKOTA STATE UNIVERSITY · PI KANEKIYO, TAKAHISA, SINGH, JAGDISH · 2024 to 2025
$1.0M
NIA NIH HHS R01 AG068034NIA NIH HHS R01 AG083981NIA NIH HHS RF1 AG068034
6 · The paper itself

Abstract

The neuroinflammation hypothesis suggests that neuroinflammation plays an important role in the progression of neurodegenerative diseases. Neuroinflammation is induced by several factors such as stimulatory signals derived from injured/dying cells, aggregated/modified proteins, and inflammatory mediators, including both proinflammatory and anti-inflammatory compounds produced by infiltrating immune cells such as microglia and astrocytes. Controlling the neuroinflammation in the brain might be a fruitful therapeutic strategy to manage the different kinds of neurodegenerative disorders. The delivery of anti-inflammatory agents to the brain is one of the challenging tasks in managing neuroinflammation due to the presence of the blood-brain barrier (BBB), which restricts the entry of the anti-inflammatory agent to the brain. With the advancement of nanoscience and nanotechnology, nanoparticle-based therapeutics are drawing great attention over conventional therapies, including high biocompatibility, more precise targeting, and the ability to cross the BBB. This review summarizes the recent progress in nanotechnology to deliver anti-inflammatory agents to the brain for the management of neurodegenerative disorders associated with neuroinflammation.

Indexed as

Anti-Inflammatory AgentsBrainDrug Delivery SystemsNanoparticlesNeurodegenerative DiseasesNeuroinflammatory DiseasesAnimalsBlood-Brain BarrierHumansNanomedicineNanotechnologyAnti-Inflammatory Agentsastrocyteblood-brain barriermicrogliananotherapeuticsneurodegenerative diseasesNeuroinflammation

Identifiers

PMID40856754
PMCPMC12582062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.